Congress and the FDA are going to be battling it out over all the cannabinoids in Hemp over the next few years
The FDA’s current stance, per Dr. Gottlieb, is that they only want to make an exception in the drug exclusion clause for 1 cannabinoid — CBD
Congress is obviously going to have a say in this matter
What’s important, in terms of investing for 2020, is figuring out what is going to be decided this year
Pure CBD looks to be the specific formulation that will be subject to legalization in Foods and Supplements as well as enforcement discretion in 2020
Pure CBD is the 1st battleground
Over the next few years, I believe we will see Full Spectrum and Broad Spectrum being negotiated, legislated and litigated
You are correct about CBN being in a different category than THC and CBD in terms of the IND preclusion
However, the safety data for CBG, CBN, CBC, etc is simply not there right now, so these cannabinoids aren’t at the same level as CBD in the eyes of the FDA
The consumer demand for CBG, CBN, CBC, etc is also nowhere near that of CBD
The current administration is also very anti-THC, something that people tend to forget
Sleek
News 
Market Data 
Discover 
